Aging Mice Treated With A GLP-1 Agonist That Is Commonly Used In Weight Loss Drugs Start Exhibiting “Age-Counteracting Effects”

wccftech.com:

This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.

By now, you must have heard of the term "Ozempic babies," which encapsulates a surprising surge in fertility and pregnancies amid an uptake in the use of GLP-1 weight loss drugs such as Novo Nordisk's Ozempic. But, in what might amount to a tantalizing discovery, these drugs have the potential to be a real-life elixir of youth, as per the results of a new non-peer reviewed study titled "Functional and multi-omic aging rejuvenation with GLP-1R agonism."

GLP-1 Agonist Reverses Age-Related Debilitation In Mice

According to the results of this study, aging mice, when treated with glucagon-like peptide-1 receptor agonist (GLP-1RA), show body-wide improvements, including in relation to physical and cognitive performance.

Related Story Eli Lilly and Company’s Tirzepatide GLP-1 Weight Loss Drug Is Now Poised To Shrink the Market for Breathing Machines

Strikingly, these age-counteracting effects become evident even at cellular levels:

What's more, researchers were able to produce these beneficial effects with a low dosage of the GLP-1 agonist that had a "negligible impact on food consumption and body weight."

While this study is yet to be peer-reviewed, its authors believe that the implications of these findings extend to "anti-aging-based therapeutics."

For the benefit of those who might not be aware, the GLP-1 hormone plays an important role in suppressing hunger and regulating the production of insulin and glucose. After a meal, GLP-1 agonists raise the level of insulin, which decreases blood glucose levels. Simultaneously, these drugs reduce the speed at which the stomach empties its contents into the small intestine, thereby increasing the feeling of fullness and satiation.

We've noted in a previous post that Eli Lilly and Company's Tirzepatide GLP-1 offering was able to reduce sleep apnea severity by around two-thirds in adults